These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35272493)

  • 1. APOE ε4 Carrier Status as Mediator of Effects of Psychotropic Drugs on Clinical Changes in Patients With Alzheimer's Disease.
    de Oliveira FF; de Almeida SS; Chen ES; Smith MC; Bertolucci PHF
    J Neuropsychiatry Clin Neurosci; 2022; 34(4):351-360. PubMed ID: 35272493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of APOE haplotypes and measures of cardiovascular risk over gender-dependent cognitive and functional changes in one year in Alzheimer's disease.
    de Oliveira FF; Pereira FV; Pivi GAK; Smith MC; Bertolucci PHF
    Int J Neurosci; 2018 May; 128(5):472-476. PubMed ID: 29064737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal lipid profile variations and clinical change in Alzheimer's disease dementia.
    de Oliveira FF; Chen ES; Smith MC; Bertolucci PHF
    Neurosci Lett; 2017 Apr; 646():36-42. PubMed ID: 28274859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Cheng YC; Huang YC; Liu HC
    Dement Geriatr Cogn Disord; 2018; 45(5-6):335-352. PubMed ID: 30041236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
    Wattmo C; Blennow K; Hansson O
    BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) ε4 allele in the elderly: retrospective analysis of data from the CREDOS study.
    Son SJ; Lee KS; Lee Y; Baek JH; Choi SH; Na DL; Seo SW; Oh BH; Hong CH
    J Clin Psychiatry; 2012 Dec; 73(12):1555-62. PubMed ID: 23146133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression.
    Mielke MM; Leoutsakos JM; Corcoran CD; Green RC; Norton MC; Welsh-Bohmer KA; Tschanz JT; Lyketsos CG
    Alzheimers Dement; 2012 May; 8(3):180-7. PubMed ID: 22301194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.
    Kennedy RE; Cutter GR; Schneider LS
    Alzheimers Dement; 2014 May; 10(3):349-59. PubMed ID: 23712001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summative Effects of Vascular Risk Factors on the Progression of Alzheimer Disease.
    Lee WJ; Liao YC; Wang YF; Lin YS; Wang SJ; Fuh JL
    J Am Geriatr Soc; 2020 Jan; 68(1):129-136. PubMed ID: 31587263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
    Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
    Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status.
    Ouk M; Wu CY; Rabin JS; Jackson A; Edwards JD; Ramirez J; Masellis M; Swartz RH; Herrmann N; Lanctôt KL; Black SE; Swardfager W
    Alzheimers Res Ther; 2021 Feb; 13(1):43. PubMed ID: 33573702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
    Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C
    Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOE ε4, Alzheimer's disease neuropathology and sleep disturbance, in individuals with and without dementia.
    Blackman J; Love S; Sinclair L; Cain R; Coulthard E
    Alzheimers Res Ther; 2022 Mar; 14(1):47. PubMed ID: 35354468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
    Wattmo C; Wallin ÅK
    Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
    Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
    Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
    Han HJ; Kim BC; Lee JY; Ryu SH; Na HR; Yoon SJ; Park HY; Shin JH; Cho SJ; Yi HA; Choi MS; Heo JH; Park KW; Kim KK; Choi SH
    Dement Geriatr Cogn Disord; 2012; 34(3-4):167-73. PubMed ID: 23051684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for cognitive and functional change in one year in patients with Alzheimer's disease dementia from São Paulo, Brazil.
    de Oliveira FF; Pivi GA; Chen ES; Smith MC; Bertolucci PH
    J Neurol Sci; 2015 Dec; 359(1-2):127-32. PubMed ID: 26671101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological modulation of cognitive and behavioral symptoms in patients with dementia due to Alzheimer's disease.
    de Oliveira FF; Bertolucci PH; Chen ES; Smith Mde A
    J Neurol Sci; 2014 Jan; 336(1-2):103-8. PubMed ID: 24189208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study.
    Wroolie TE; Kenna HA; Williams KE; Powers BN; Holcomb M; Lazzeroni L; Rasgon NL
    Acta Neurol Scand; 2009 Mar; 119(3):172-9. PubMed ID: 18705678
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.